App-Quantinova.ai

Brain metastasis (BM) prediction by transcriptomic profiling in triple-negative breast cancer (TNBC).

Renata Duchnowska - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

RespondR signature to predict response in TNBC patients treated with adjuvant taxane based chemotherapy in TCGA dataset.

Steven Allen Buechler - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

taxane

A phase 1 window of opportunity study of valproic acid (VPA) in breast cancer testing a gene expression biomarker.

Adam Louis Cohen - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Valproic Acid

Multi-institutional study of triple negative breast cancer stratification by a metric that quantifies cell cycling kinetics.

Sergey Klimov - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Performance of genomic data strategies for cancer precision medicine across distinct contexts and ethnicities.

Andrea Garofalo - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Methadone hydrochloride

Patient-reported outcomes in a multicenter randomized study of in-person versus telephone disclosure of genetic test results for cancer susceptibility.

Angela R. Bradbury - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Safety of multiplex gene testing for inherited cancer risk: Interim analysis of a clinical trial.

Allison W. Kurian - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

TP53

Effects of risk-reducing surgery on libido, self-image, and psychological status among BRCA mutation carriers.

Olga Ivanov - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Preliminary outcomes of a primary care-based skin cancer screening program.

Laura Ferris - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Yield of Multiplex Panel Testing Exceeds Expert Opinion and Validated Prediction Models

Gregory Idos - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

TP53

Conflicting interpretation of Genetic Variants and Cancerer Risk by Commercial Laboratories as Assessed by the Prospective Registry of Multiplex Testing (PROMPT)

Judith Balmana - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Prevalence of Clonal Hematopoiesis in Patients with Advanced Cancer

Ahmet Zehir - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

A prospective analysis of individual body fat depots and risk of developing cancer: Insights from the Dallas heart study.

Arjun Gupta - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Features of the metabolic syndrome and survival after a diagnosis of breast cancer in the Womens Health Initiative (WHI).

Jennifer Lynn Beebe-Dimmer - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Prospective registry of multiplex testing (PROMPT): A web-based platform to assess cancer risk of genetic variants.

Michael Francis Walsh - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Cancer in primary immunodeficiency diseases: An analysis of cancer incidence in the United States immune deficiency network (USIDNET) registry.

Paul Mayor - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Identification of lynch syndrome (LS) in patients (pts) without prior LS-associated cancer.

Matthew B. Yurgelun - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Clinical characterization of DNA mismatch repair deficiency (MMR-D) in endometrial cancer (EC).

Karen Anne Cadoo - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Evaluation of microsatellite instability (MSI) status in 11,573 diverse solid tumors using comprehensive genomic profiling (CGP).

Michael J. Hall - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Baseline cancer screening findings from the NCI Li-Fraumeni syndrome study.

Phuong L. Mai - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

TP53

Filters

41730 Abstracts